MAZE THERAPEUTICS, INC. Shares Outstanding (Cover Page)
MAZE THERAPEUTICS, INC. (MAZE) had Shares Outstanding (Cover Page) of 55.55 million shares as of 2026-08-05, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-11
- 2026-08-05: Entity Common Stock, Shares Outstanding 55.55M shares.
- 2026-05-07: Entity Common Stock, Shares Outstanding 55.35M shares.
- 2025-11-03: Entity Common Stock, Shares Outstanding 48.12M shares.
- 2025-08-06: Entity Common Stock, Shares Outstanding 43.85M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-08-05 | 55.55M shares 10-Q · filed 2026-08-11 |
| 2026-05-07 | 55.35M shares 10-Q · filed 2026-05-12 |
| 2025-11-03 | 48.12M shares 10-Q · filed 2025-11-06 |
| 2025-08-06 | 43.85M shares 10-Q · filed 2025-08-12 |
| 2025-05-08 | 43.80M shares 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |